RecruitingNot ApplicableNCT06726356

Value of Bronchoalveolar Lavage with Acetylcysteine in the Treatment of Bronchiectasis.

Efficacy and Safety of Bronchoalveolar Lavage with Acetylcysteine in the Treatment of Bronchiectasis with Infection in Adults: a Multicentre, Blinded, Randomised Controlled Study.


Sponsor

First Affiliated Hospital of Ningbo University

Enrollment

180 participants

Start Date

Aug 14, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

Bronchiectasis is a clinical syndrome characterised by chronic cough, profuse sputum and/or intermittent haemoptysis, with or without shortness of breath and respiratory failure of varying severity, and abnormal thickening and dilatation of the bronchial walls as seen on lung imaging. Nebulised inhalation of N-acetylcysteine has been shown to significantly improve symptoms, shorten the length of hospital stay, reduce the rate of re-hospitalisation within six months, and improve lung function in patients with bronchiectasis with a high degree of safety. There have been no studies on the efficacy and safety of bronchoscopic irrigation with N-acetylcysteine solution in the treatment of bronchiectasis. The aim of this study was to investigate whether bronchoscopic acetylcysteine lavage combined with conventional treatment is more beneficial to patients with bronchiectasis than conventional treatment combined with conventional bronchoalveolar lavage and conventional treatment without bronchoscopy, respectively.


Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This study tests whether flushing the airways with an acetylcysteine (a mucus-thinning medication) solution during bronchoscopy can help clear mucus and bacteria more effectively in patients with bronchiectasis (a condition where the airways are permanently widened and filled with mucus) during a flare-up. **You may be eligible if...** - Age 18–80 - CT scan showing bronchiectasis - Currently experiencing a flare-up (acute exacerbation) with symptoms like increased cough, sputum, chest tightness, or wheezing **You may NOT be eligible if...** - Have bronchiectasis caused by cystic fibrosis - Have severe kidney or liver disease - Are allergic to acetylcysteine - Are pregnant or breastfeeding - Have had a recent major bleed in the airways Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREBronchoalveolar Lavage

Bronchoalveolar lavage with saline or saline-acetylcysteine solution on the basis of conventional clinical treatment, with a volume of 90 ml per target lung lobe, up to a maximum of 2 lobes, and a total volume of up to 180 ml.


Locations(1)

The First Affiliated Hospital of Ningbo University

Ningbo, Zhejiang, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06726356


Related Trials